Pricing for rare disease and curative therapies: What's fair?

Pricing for rare disease and curative therapies: What's fair?

As policymakers, payers and other stakeholders grapple with the question of what the healthcare system can afford to pay, the high cost and risk involved in developing innovative therapies has led to the question: what is fair? 

In early 2020, CRA conducted research with a broad range of US stakeholders – including payers, physicians, patients, pharma/biotech manufacturers and others – to evaluate what these stakeholders believe is fair with respect to prices of therapies to treat rare conditions. In this article, Andrew Parece, Matthew Majewski, Kristen Backor, and Joseph Black present the findings from research with 50 payer representatives from large commercial health plans and pharmacy benefit managers. The research was designed to provide insights into their perceptions of whether the prices of therapies are fair, and how perceptions of fairness depend on characteristics of the therapy, the condition, the patient population, existing price benchmarks and other attributes of the treatment and patient.

To read the article published in Pharmaceutical Executive, click here.